<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418402</url>
  </required_header>
  <id_info>
    <org_study_id>2017-27</org_study_id>
    <secondary_id>2017-A01640-53</secondary_id>
    <nct_id>NCT03418402</nct_id>
  </id_info>
  <brief_title>Post Operative Pain After Laparoscopic Hysterectomy Using Airseal® Versus Standard Insufflation System</brief_title>
  <acronym>AIRSEAL</acronym>
  <official_title>Post Operative Pain After Laparoscopic Hysterectomy Using Airseal® Versus Standard Insufflation System: A Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Airseal® is an insufflation management system for laparoscopic surgery which provides stable&#xD;
      pneumoperitoneum, continuous smoke evacuation and valve-free access to the abdominal cavity.&#xD;
      It allows an optimal exposure with a low-pression pneumoperitoneum, which is rarely possible&#xD;
      with our standard insufflation system under a pneumoperitoneum of 12 millimetres of&#xD;
      mercury(mmHg).&#xD;
&#xD;
      The objective of this study is to compare the use of Airseal® system with a low pression&#xD;
      pneumoperitoneum and our standard insufflation system usually used in our center in term of&#xD;
      postoperative abdominal pain after laparoscopic hysterectomy for benign disease.&#xD;
&#xD;
      This superiority prospective randomized trial is designed to include all patients &gt; 18 years&#xD;
      old referred for laparoscopic total hysterectomy for benign disease (with or without uni or&#xD;
      bilateral annexectomy). Each patient would be randomized to one of this two following groups&#xD;
      :&#xD;
&#xD;
        -  &quot; Airseal® &quot; group : use of AIRSEAL® to obtain stable low pression laparoscopy with a 8&#xD;
           to 10 mmHg pneumoperitoneum.&#xD;
&#xD;
        -  &quot; Standard laparoscopy &quot; group : laparoscopy realised with our usual insufflation system&#xD;
           and a 12 to 15 mmHg pneumoperitoneum.&#xD;
&#xD;
      The primary end point is mean intensity of abdominal pain six hours after the end of surgery&#xD;
      (H6), measured by simple numerical scale (ENS).&#xD;
&#xD;
      The secondary end points are:&#xD;
&#xD;
        -  peroperative endpoints : operative time, blood loss, use of additional ways of&#xD;
           increasing exposure, peroperative complications, conversion to laparotomy, feeling of&#xD;
           the surgeon regarding the difficulty of the surgery (measured by a simple numerical&#xD;
           scale)&#xD;
&#xD;
        -  early postoperative endpoints : intensity of abdominal pain at the entry in recovery&#xD;
           room (H0), at twelve hours after the end of surgery (H12), twenty four hours (H24) and&#xD;
           forty eight hours (H48) ; intensity of scapular pain at the same times (H0, H6, H12, H24&#xD;
           and H48), need for analgesic administration (regarding to the standardized analgesic&#xD;
           protocol), difference in the hemoglobin level before surgery and the first day after,&#xD;
           early postoperative complications, necessity of a second surgery and the reason, length&#xD;
           of hospital stay.&#xD;
&#xD;
        -  late postoperative end points : estimated time to return to optimal quality of life,&#xD;
           global satisfaction of patients evaluated by the Quality Of Life Questionnaire Short&#xD;
           Form 12.&#xD;
&#xD;
      It will be estimate that the use of Airseal® will reduce the mean abdominal pain at H6 post&#xD;
      operative of 1 point on the simple numerical scale compared to our standard insufflation&#xD;
      system, with a standard deviation of 1,5. Type 1 and 2 errors were set to the usual levels of&#xD;
      0,05 and 0,20 respectively (power of 80%). Assuming a 10% withdrawal rate, the sample size&#xD;
      would be 80 patients (40 patients in each group).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">January 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pain by simple numerical scale</measure>
    <time_frame>six hours</time_frame>
    <description>The primary end point is mean intensity of abdominal pain measured by simple numerical scale. a score of 0 to 10 best describes the importance of the patient's pain. The score 0 corresponds to &quot;no pain&quot;. Note 10 is the maximum &quot;pain&quot; imaginable</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Laparoscopic Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Airseal®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard insufflator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Airseal®</intervention_name>
    <description>Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.</description>
    <arm_group_label>Airseal®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard insufflator</intervention_name>
    <description>Standard insufflator</description>
    <arm_group_label>Standard insufflator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients at least 18 years old.&#xD;
&#xD;
          -  Patients who agreed to participate in the study and signed informed consent.&#xD;
&#xD;
          -  Surgical indication by laparoscopy of total interadnexal hysterectomy or associated&#xD;
             with unilateral or bilateral adnexectomy, for benign pathology, without any other&#xD;
             associated surgical procedure.&#xD;
&#xD;
          -  Absence of contraindications to the taking of analgesics provided for in the&#xD;
             standardized protocols of analgesia per and post-operative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients at least 18 years old.&#xD;
&#xD;
          -  Patients who agreed to participate in the study and signed informed consent.&#xD;
&#xD;
          -  Surgical indication by laparoscopy of total interadnexal hysterectomy or associated&#xD;
             with unilateral or bilateral adnexectomy, for benign pathology, without any other&#xD;
             associated surgical procedure.&#xD;
&#xD;
          -  Absence of contraindications to the taking of analgesics provided for in the&#xD;
             standardized protocols of analgesia per and post-operative.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aubert AGOSTINI, PU-PH</last_name>
    <phone>491383785</phone>
    <phone_ext>+33</phone_ext>
    <email>aubert.agostini@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Tourette, PH</last_name>
    <phone>491383785</phone>
    <phone_ext>+33</phone_ext>
    <email>claire.tourette@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aubert AGOSTINI, PU-PH</last_name>
      <phone>491383785</phone>
      <phone_ext>+33</phone_ext>
      <email>aubert.agostini@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Aubert AGOSTINI, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

